These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16627760)

  • 1. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
    Flotho C; Coustan-Smith E; Pei D; Iwamoto S; Song G; Cheng C; Pui CH; Downing JR; Campana D
    Blood; 2006 Aug; 108(3):1050-7. PubMed ID: 16627760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CASP8AP2 is a promising prognostic indicator in pediatric acute lymphoblastic leukemia.
    Jiao Y; Cui L; Gao C; Li W; Zhao X; Liu S; Wu M; Deng G; Li Z
    Leuk Res; 2012 Jan; 36(1):67-71. PubMed ID: 21696825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
    Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
    Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of
    Cui L; Gao C; Wang CJ; Liu SG; Wu MY; Zhang RD; Li ZG
    Pediatr Hematol Oncol; 2020 Nov; 37(8):732-746. PubMed ID: 32804017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.
    Juárez-Velázquez R; Reyes-León A; Salas-Labadía C; Rivera-Luna R; Velasco-Hidalgo L; López-Hernández G; López-Santiago N; Paredes-Aguilera R; Domínguez-López A; Bernáldez R; Pérez-Vera P
    Leuk Lymphoma; 2014 Oct; 55(10):2305-11. PubMed ID: 24397596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of two CpG sites upstream of CASP8AP2 promoter influences gene expression and treatment outcome in childhood acute lymphoblastic leukemia.
    Li ZG; Jiao Y; Li WJ; Deng GR; Cui L; Gao C; Zhao XX; Wu MY; Jia HT
    Leuk Res; 2013 Oct; 37(10):1287-93. PubMed ID: 23953914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
    Flotho C; Coustan-Smith E; Pei D; Cheng C; Song G; Pui CH; Downing JR; Campana D
    Blood; 2007 Aug; 110(4):1271-7. PubMed ID: 17456722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of CASP8AP2 gene methylation in childhood acute lymphoblastic leukemia].
    Liu FF; Liu X; Wang KL; Li WJ; Deng GR; Gao C; Zhao XX; Wu MY; Cui L; Li ZG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):6-11. PubMed ID: 25687037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia.
    Yang YL; Lin SR; Chen JS; Lin SW; Yu SL; Chen HY; Yen CT; Lin CY; Lin JF; Lin KH; Jou ST; Hu CY; Chang SK; Lu MY; Chang HH; Chang WH; Lin KS; Lin DT
    Leuk Res; 2010 Jan; 34(1):18-23. PubMed ID: 20109966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
    Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
    Gaipa G; Basso G; Biondi A; Campana D
    Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
    Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
    Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays.
    Willenbrock H; Juncker AS; Schmiegelow K; Knudsen S; Ryder LP
    Leukemia; 2004 Jul; 18(7):1270-7. PubMed ID: 15152267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
    Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
    Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.